$YS News
Last published 2y ago
- 2y agoLSBYSLakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of PakistanGlobeNewswireGAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global leader in the discovery, development, manufacturing, and delivery of
- 2y agoYSYS Biopharma Announces Name Change to LakeShore BiopharmaPR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Announces Results of Extraordinary General MeetingPR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive OfficerPR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RulePR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoYSYS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024PR NewswireYS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus VaccinePR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024PR NewswireYS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies VaccinePR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Announces Full Repayment of US$40,000,000 Loan FacilityPR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese SubsidiariesPR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024PR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the MeetingPR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSShareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.PR NewswireYi Zhang and shareholders representing over 59.2% of the outstanding shares of YS Biopharma Co., Ltd. (the "Company" or "YS") (NASDAQ: YS) (the...
- 2y agoYSYS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate GovernancePR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and...
- 2y agoYSYS Biopharma Announces Appointment of New DirectorsPR NewswireYS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company", and together with its subsidiaries, "YS Group"), a global biopharmaceutical...
- 2y agoYSYS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.PR NewswireYS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Announces US$40 Million Private Placement FinancingPR NewswireYS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical company...
- 2y agoYSDiamond Equity Research Releases Update Note on YS Biopharma Co., Ltd. (NASDAQ: YS)GlobeNewswireNEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies, has released an update note on YS Biopharma Co., Ltd.
- 2y agoYSYS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024PR NewswireYS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical company...
- 2y agoYSYS Biopharma Announces Changes to its Board CommitteesPR NewswireYS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General MeetingPR NewswireYS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 2y agoYSYS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023PR NewswireYS Biopharma Co., Ltd. ("YS Biopharma" or the "Company") (NASDAQ: YS), a global biopharmaceutical company, today announced that upon the receipt of a ...
- 2y agoYSNoble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price TargetPR NewswireYS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 3y agoYSYS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies VaccinePR NewswireYS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 3y agoYSYS Biopharma Announces Receipt of Nasdaq NoticePR NewswireYS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
- 3y agoYSYS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies VaccinePR NewswireGAITHERSBURG, Md., Sept. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,
- 3y agoYSDiamond Equity Research Releases Update Note on YS Biopharma Co., Ltd. (NASDAQ: YS)GlobeNewswireNEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released update note on YS Biopharma Co., Ltd. (NASDAQ:YS).
- 3y agoYSYS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus InfectionPR NewswireGAITHERSBURG, Md., Sept. 15, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,
- 3y agoYSYS Biopharma to Participate in Participate in Citi's 18th Annual Biopharma ConferencePR NewswireGAITHERSBURG, Md., Sept. 5, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,
- 3y agoYSYS Biopharma Announces Purchase of Shares by Company OfficersPR NewswireGAITHERSBURG, Md., Aug. 24, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,
- 3y agoYSDiamond Equity Research Initiates Coverage on YS Biopharma Co., Ltd. (NASDAQ: YS)GlobeNewswireNEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of YS Biopharma Co., Ltd. (NASDAQ:YS).
- 3y agoYSYS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024PR NewswirePipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues Gross margin increases to 80.3%; balance sheet remains strong GAITHERSBURG, Md., Aug. 15, 2023 /PRNewswire/ -- YS
- 3y agoYSYS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023PR NewswireTotal revenues increase by 36.3% year-over-year; gross margin improves to 77.7%; balance sheet remains robust Company's PIKA rabies vaccine approved for Phase III clinical trials in Singapore, the Philippines, and
- 3y agoYSYS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023PR NewswireGAITHERSBURG, Md., July 21, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,
- 3y agoPRPHQSGVIOTYSDiamond Equity Research to Host Global Select Emerging Growth Invitational Virtual Investor Conference on June 13th, 2023GlobeNewswireNEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Global Select Spotlight Emerging Growth Invitational Investor
- 3y agoYSYS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDAPR NewswireGAITHERSBURG, Md., June 1, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,
- 3y agoYSYS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023PR NewswireGAITHERSBURG, Md., May 18, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,
- 3y agoYSYS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in PakistanPR NewswireGAITHERSBURG, Md., May 16, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,
- 3y agoYSYS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023PR NewswireFY2023 Revenues Increased by Approximately 30% Year Over Year GAITHERSBURG, Md., April 18, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global
- 3y agoYSYS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical StudyPR NewswireThe trial met its primary endpoint of superior immunogenicity of PIKA COVID-19 Vaccine vs inactivated COVID-19 vaccine, measured by GMT of neutralizing antibody against Omicron virus on Day 14, with statistical
- 8y agoYSJOBSShareholders of YS Biopharma Announce an Extraordinary General MeetingPR NewswireShareholders of YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma"), a global biopharmaceutical company dedicated to discovering, developing,...